Cyclopharm (ASX:CYC) has posted its strongest half-year performance on record, underpinned by accelerating adoption of its Technegas technology in the US, robust international sales, and fresh intellectual property milestones that extend the company’s growth runway.
R&D
New Stories
-
Cyclopharm reports record first-half revenue and expanding US momentum
August 28, 2025 - - Latest News -
Cartherics secures Chinese patent to boost immune cell function in solid tumours
August 27, 2025 - - Latest News -
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 - - Latest News -
Starpharma advances dendrimer platform with clinical, commercial, and strategic progress
August 27, 2025 - - Latest News -
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 - - Latest News -
Biome achieves breakthrough year with first profit and rapid global expansion
August 27, 2025 - - Latest News -
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 26, 2025 - - Latest News